This phase I study is assessing how safe, tolerable and effective targeted therapy (mosunetuzumab) is in people with relapsed or refractory chronic lymphocytic leukaemia.
This trial is treating patients with chronic lymphocytic leukaemia.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Eligible participants will receive weekly step-up dosing of mosunetuzumab until the target dose is reached, after which mosunetuzumab will be administered once every 21 days for up to 17 cycles (cycle = 21 days) or until disease progression or unacceptable toxicity, whichever occurs first. Mosunetuzumab will be administered subcutaneously. Tocilizumab will also be given (intravenously) as needed for cytokine release syndrome (CRS) events.
Recruiting Hospitals Read More